SYK:NYE-Stryker Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 358.71

Change

+8.33 (+2.38)%

Market Cap

USD 41.39B

Volume

1.40M

Analyst Target

USD 217.70
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Stryker Corp is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 186.58B
MDT Medtronic PLC

N/A

USD 112.28B
BSX Boston Scientific Corp

N/A

USD 107.55B
EW Edwards Lifesciences Corp

N/A

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 26.16B
STE STERIS plc

N/A

USD 21.09B
PHG Koninklijke Philips NV ADR

N/A

USD 18.20B
SNN Smith & Nephew SNATS Inc

N/A

USD 10.70B
BIO Bio-Rad Laboratories Inc

N/A

USD 7.89B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 7.89B

ETFs Containing SYK

CIB0:XETRA VanEck Bionic Engineering.. 10.92 % 0.00 %

N/A

USD 6.36M
UMDV:SW iShares US Medical Device.. 10.32 % 0.00 %

N/A

USD 0.18B
CYBG:LSE VanEck Bionic Engineering.. 9.87 % 0.00 %

N/A

USD 6.05M
LIFE-B:CA Evolve Global Healthcare .. 5.55 % 0.00 %

N/A

CAD 0.01B
HHL-U:CA Harvest Healthcare Leader.. 5.33 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 5.33 % 0.00 %

N/A

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.91 % 0.00 %

N/A

USD 0.15B
ZWHC:CA BMO Covered Call Health C.. 4.78 % 0.00 %

N/A

CAD 0.01B
CWS AdvisorShares Focused Equ.. 4.41 % 0.68 %

N/A

USD 0.14B
MHCD:CA Middlefield Healthcare Di.. 4.31 % 0.00 %

N/A

CAD 0.16B
AGNG Global X Aging Population.. 3.59 % 0.00 %

N/A

USD 0.06B
TDOC:CA TD Global Healthcare Lead.. 2.25 % 0.00 %

N/A

CAD 0.07B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.18 % 0.00 %

N/A

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.18 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.18 % 0.00 %

N/A

N/A
FTCS First Trust Capital Stren.. 2.05 % 0.60 %

N/A

USD 8.64B
HTEC Robo Global® Healthcare .. 1.84 % 0.00 %

N/A

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.79 % 0.00 %

N/A

USD 0.08B
DOCT:LSE L&G Healthcare Breakthrou.. 1.79 % 0.00 %

N/A

USD 0.08B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

USD 5.55B
LNGR 0.00 % 0.50 %

N/A

N/A
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.75 %

N/A

CAD 0.08B
WBIL WBI BullBear Quality 3000.. 0.00 % 1.07 %

N/A

USD 0.04B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.30B
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

CAD 0.33B
BIBL Northern Lights Fund Trus.. 0.00 % 0.35 %

N/A

USD 0.37B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
TACE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.79% 81% B- 92% A
Dividend Return 0.27% 67% D+ 13% F
Total Return 20.05% 81% B- 91% A-
Trailing 12 Months  
Capital Gain 28.56% 73% C 79% B-
Dividend Return 1.38% 57% F 17% F
Total Return 29.94% 73% C 77% C+
Trailing 5 Years  
Capital Gain 81.61% 95% A 81% B-
Dividend Return 6.70% 57% F 22% F
Total Return 88.31% 95% A 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.45% 73% C 76% C+
Dividend Return 12.61% 77% C+ 74% C
Total Return 1.16% 57% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 21.61% 77% C+ 53% F
Risk Adjusted Return 58.34% 93% A 84% B
Market Capitalization 41.39B 97% N/A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.40 59% 15%
Price/Book Ratio 7.22 23% 12%
Price / Cash Flow Ratio 36.19 21% 7%
Price/Free Cash Flow Ratio 29.24 16% 6%
Management Effectiveness  
Return on Equity 17.98% 97% 78%
Return on Invested Capital 11.04% 94% 67%
Return on Assets 6.87% 94% 82%
Debt to Equity Ratio 58.63% 33% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.